New medication for rare form of kidney disease still expected to complete stage III trial this year

Because chronic kidney disease starts slowly with few symptoms, it may not be diagnosed before much of the damage has been done.However, it still may take some more time to complete the stage three trial, as the FDA has “suggested that we shift our primary endpoint from 24 weeks to 36 weeks to have greater data.

Atrasentan was initially developed by the company AbbVie to reduce the onset of end-stage kidney disease and proteinuria in patients with diabetes. The data collected through the AbbVie research allowed Chinook to accelerate the clinical trial process, cutting out years of animal-model studies.is released when the body responds to infection, leading researchers to believe this form of neuropathy may be connected to the immune system.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

New medication for rare form of kidney disease still expected to complete stage III trial this yearAs many as 50 per cent of patients with IgA Nephropathy will reach kidney failure — via healthing_ca IgaNephropathy healthing Kidneydisease
Source: nationalpost - 🏆 10. / 80 Read more »

New medication for rare form of kidney disease still expected to complete stage III trial this yearAs many as 50 per cent of patients with IgA Nephropathy will reach kidney failure — via healthing_ca IgaNephropathy healthing Kidneydisease
Source: VancouverSun - 🏆 49. / 61 Read more »